287 related articles for article (PubMed ID: 19234167)
1. Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells.
Gerner MY; Mescher MF
J Immunol; 2009 Mar; 182(5):2726-37. PubMed ID: 19234167
[TBL] [Abstract][Full Text] [Related]
2. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
Tanaka Y; Koido S; Ohana M; Liu C; Gong J
J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
[TBL] [Abstract][Full Text] [Related]
3. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
4. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo.
Kleindienst P; Brocker T
J Immunol; 2003 Mar; 170(6):2817-23. PubMed ID: 12626531
[TBL] [Abstract][Full Text] [Related]
5. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
6. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells.
del Rio ML; Rodriguez-Barbosa JI; Kremmer E; Förster R
J Immunol; 2007 Jun; 178(11):6861-6. PubMed ID: 17513734
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
8. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
9. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
10. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
[TBL] [Abstract][Full Text] [Related]
11. Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo.
Wolf AJ; Linas B; Trevejo-Nuñez GJ; Kincaid E; Tamura T; Takatsu K; Ernst JD
J Immunol; 2007 Aug; 179(4):2509-19. PubMed ID: 17675513
[TBL] [Abstract][Full Text] [Related]
12. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses.
Gerner MY; Casey KA; Mescher MF
J Immunol; 2008 Jul; 181(1):155-64. PubMed ID: 18566380
[TBL] [Abstract][Full Text] [Related]
13. Indirect minor histocompatibility antigen presentation by allograft recipient cells in the draining lymph node leads to the activation and clonal expansion of CD4+ T cells that cause obliterative airways disease.
Richards DM; Dalheimer SL; Ehst BD; Vanasek TL; Jenkins MK; Hertz MI; Mueller DL
J Immunol; 2004 Mar; 172(6):3469-79. PubMed ID: 15004147
[TBL] [Abstract][Full Text] [Related]
14. Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells.
Brocker T
J Exp Med; 1997 Oct; 186(8):1223-32. PubMed ID: 9334361
[TBL] [Abstract][Full Text] [Related]
15. Fc gamma RIIB regulates nasal and oral tolerance: a role for dendritic cells.
Samsom JN; van Berkel LA; van Helvoort JM; Unger WW; Jansen W; Thepen T; Mebius RE; Verbeek SS; Kraal G
J Immunol; 2005 May; 174(9):5279-87. PubMed ID: 15843524
[TBL] [Abstract][Full Text] [Related]
16. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.
Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F
J Immunol; 1999 Jul; 163(1):77-81. PubMed ID: 10384102
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses.
Bauman SK; Nichols KL; Murphy JW
J Immunol; 2000 Jul; 165(1):158-67. PubMed ID: 10861048
[TBL] [Abstract][Full Text] [Related]
18. Dual role of dendritic cells in the induction and down-regulation of antigen-specific cutaneous inflammation.
Krasteva M; Kehren J; Horand F; Akiba H; Choquet G; Ducluzeau MT; Tédone R; Garrigue JL; Kaiserlian D; Nicolas JF
J Immunol; 1998 Feb; 160(3):1181-90. PubMed ID: 9570532
[TBL] [Abstract][Full Text] [Related]
19. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
20. Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk.
Benigni F; Zimmermann VS; Hugues S; Caserta S; Basso V; Rivino L; Ingulli E; Malherbe L; Glaichenhaus N; Mondino A
J Immunol; 2005 Jul; 175(2):739-48. PubMed ID: 16002669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
